2 recruiting. 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Recruiting 2 |
| Phase 3 | 1 | Recruiting 1 |
Follow Agitation: new trials by email Literature Review of Agitation trials Research Report on Agitation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease BMS-986368, Placebo - Agitation, Alzheimer Disease | Phase 2 | Recruiting | Celgene | 120 | 2025-06-09 | 2026-10-06 |
| Acute Agitation in Emergency Psychiatry Sublingual Dexmedetomidine, Buccal midazolam, Oral lorazepam - Agitation | Phase 2 / Phase 3 | Recruiting | Lone Baandrup | 132 | 2024-12-30 | 2025-01-01 |
Psychomotor Agitation (2) · Alzheimer Disease (1)
Aberrant Motor Behavior in Dementia (2) · Behavior (2) · Behavioral Symptoms (2) · Dyskinesias (2) · Nervous System Diseases (2) · Neurobehavioral Manifestations (2) · Neurologic Manifestations (2) · Pathological Conditions, Signs and Symptoms (2) · Psychomotor Disorders (2) · Signs and Symptoms (2) · Brain Diseases (1) · Central Nervous System Diseases (1) · Dementia (1) · Mental Disorders (1) · Neurocognitive Disorders (1)
Lorazepam (1)
Celgene (1) · Lone Baandrup (1)
Argentina (1) · Australia (1) · China (1) · Denmark (1) · United States (1)
2023 (1)